Article
In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification.
Blood - 18 Sept 2014
Wang Yu, Wu De-Pei, Liu Qi-Fa, Qin Ya-Zhen, Wang Jing-Bo, Xu Lan-Ping, Liu Yan-Rong, Zhu Hong-Hu, Chen Jia, Dai Min, Huang Xiao-Jun
Abstract excerpt
We asked whether minimal residual disease (MRD) determined by RUNX1/RUNX1T1 transcript levels could identify allogeneic hematopoietic stem cell transplantation (allo- HSCT) t(8;21) (q22;q22) acute myeloid leukemia patients who are at high risk for relapse, together with the impact of c-KIT mutations. Ninety-two consecutive adult t(8;21) patients who received allo-HSCT in complete remission were enrolled. MRD...
Topics
- Adolescent
- Adult
- Chromosomes, Human, Pair 21
- Chromosomes, Human, Pair 8
- Core Binding Factor Alpha 2 Subunit
- Female
- Hematopoietic Stem Cell Transplantation
- Humans
- Leukemia, Myeloid, Acute
- Male
- Middle Aged
- Mutation
- Neoplasm, Residual